“Lupus can increase the risk of pregnancy complications, so proper management of this condition during pregnancy is important for both the mother and her developing baby.” – Christina Chambers, Ph.D. Master of Public Health
San Diego (PRWEB)
February 1, 2023
A call for groundbreaking new research on the treatment of lupus during pregnancy is underway. Led by world-renowned epidemiologist Christina Chambers, Ph.D., M.P.H., at the University of California, San Diego, this observational study is a CDC-recommended organization that provides evidence-based information about drugs, diseases, and vaccines. For the non-profit MotherToBaby, it’s the first of its kind. , including herbal supplements during pregnancy and lactation.
This study will recruit 400 pregnant women over a 5-year period and evaluate the use of the lupus drug Benlysta® (belimumab) during pregnancy. Benlysta® is used to treat systemic lupus erythematosus (SLE), the most common type of lupus, and lupus nephritis. Currently, information on drug use during pregnancy is limited.
This study is MotherToBaby’s first study to focus on lupus-specific treatments, and participants will be enrolled in the MotherToBaby Pregnancy Research Program. Dr. Chambers, Co-Director and Chief of the Division of Environmental Sciences and Health, Department of Pediatrics, University of California, San Diego, said: Due to the potential for complications during pregnancy, proper management of this condition during pregnancy is important for both the mother and the growing baby. I will do my best to collect information about pregnancies in which this drug has been used.
This study enrolls pregnant and recently pregnant people exposed to Benlysta® and provides important information regarding the use of this drug during pregnancy. Participants will not be asked to change any part of their healthcare routine, including medications, nor will they be asked to travel.
MotherToBaby Pregnancy Study Details
The MotherToBaby Pregnancy Study is conducted by the nonprofit Teratology Information Professionals Organization (OTIS) and is coordinated by the Center for Better Beginnings at UC San Diego. OTIS is a professional scientific body of individuals involved in assessing and assessing pregnancy and lactation risks from environmental exposures. Provides obstetrics and gynecology, pediatrics, genetics, dysmorphology, perinatal epidemiology, teratology, behavioral teratology, pharmacy, genetic counseling, nursing, midwifery, maternal and child health, public health, and MotherToBaby services to members and researchers conducting MotherToBaby pregnancy studies.
MotherToBaby is a resource proposed by many federal agencies, including the Centers for Disease Control and Prevention (CDC). MotherToBaby is supported by the U.S. Department of Health and Human Services (HHS) Health Resource Services Administration (HRSA) as part of a zero percentage award totaling $6,000,000 funded from nongovernmental sources. The content of this release is the author’s and does not necessarily represent her official views or endorsements of HRSA, HHS, or the US Government. For more information on MotherToBaby and OTIS, visit MotherToBaby.org.
Media Contact: Nicole Chavez, email@example.com, 619-368-3259
Share articles on social media or email: